The first healthy volunteer has been dosed in a trial evaluating ISM001-055, Insilico Medicine’s artificial intelligence (AI)-discovered therapy candidate for idiopathic pulmonary fibrosis (IPF). “We are very pleased to see Insilico Medicine’s first antifibrotic [treatment] candidate entering into the clinic,” Feng Ren, PhD, Insilico’s chief strategy officer, said…
Cudetaxestat (BLD-0409), an investigational therapy for idiopathic pulmonary fibrosis (IPF), showed favorable safety and tolerability in a Phase 1 trial of healthy volunteers. Developed by Blade Therapeutics, cudetaxestat is designed to block the activity of an enzyme called autotaxin that produces a pro-scarring (fibrotic) signaling molecule. This enzyme commonly…
Chiesi announced it has secured from UCB rights to zampilimab, a monoclonal antibody being investigated to treat idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Under the agreement, Chiesi acquired global exclusive rights to develop and manufacture the potential antifibrotic therapy, and to market it should it be approved.
PF Warriors has partnered with online shopping site Joe & Bella to make holiday gift-giving easier for people with pulmonary fibrosis (PF) — while raising funds for the nonprofit’s mission of increasing awareness of PF and other interstitial lung diseases (ILDs). Products sold at Joe & Bella…
NXP002, Nuformix’s experimental inhaled therapy for idiopathic pulmonary fibrosis (IPF), achieves significant levels in the lungs and lowers the production of molecules that promote scarring, according to preclinical studies involving rats, the company announced. “We’re delighted with the positive readout of this data so far and it further…
Researchers have now compiled the most comprehensive molecular atlas, or roadmap, to date of healthy human lungs and their early development, leading to the identification of nearly 9,000 proteins whose production changes with age. The data, open to the public through an online platform called LungMAP, are expected to help…
LYT-100 (deupirfenidone), an experimental oral therapy containing a similar active ingredient to Esbriet, was well-tolerated at all tested doses — and did not reach the maximum tolerated dose or MTD — in a Phase 1 trial conducted in healthy volunteers. PureTech Health, which is developing LYT-100 for…
The American Thoracic Society (ATS) has premiered a docuseries called “Helping the World to Breathe,” showcasing the society’s commitment to advancing care for people with lung diseases. Over 16 episodes, the series highlights stories from clinicians, researchers, and patients collaborating to advance care. For example, scientists and patients at…
The National Institutes of Health (NIH) has awarded a grant to support research into immune mechanisms that could allow for the reversal of fibrosis, or tissue scarring, in idiopathic pulmonary fibrosis (IPF). The $469,034 award went to Narendiran Rajasekaran, PhD, and Archana Varadaraj, PhD, both of whom are assistant…
Scientists have developed a new lab-grown three-dimension (3D) microtissue model that replicates the key features of the idiopathic pulmonary fibrosis (IPF) microenvironment better than other cellular and animal models, and that enables more robust screening of potential therapies. When the model was generated using lung cells collected from IPF…
Get regular updates to your inbox.
